2020
LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment
Llovet J, El-Khoueiry A, Vogel A, Madoff D, Finn R, Ogasawara S, Ren Z, Mody K, Li J, Siegel A, Dubrovsky L, Kudo M. LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment. Annals Of Oncology 2020, 31: s702-s703. DOI: 10.1016/j.annonc.2020.08.1132.Peer-Reviewed Original Research
2015
10:10 AM Abstract No. 2 Muliticenter trial of the VenaTech convertible filter: a novel approach to IVC filtration
Hohenwalter E, Stone J, O’Moore P, Smith S, Selby J, Lewandowski R, Samuels S, Kiproff P, Trost D, Handel J, Gandras E, Madoff D, Vlahos A, Rilling W. 10:10 AM Abstract No. 2 Muliticenter trial of the VenaTech convertible filter: a novel approach to IVC filtration. Journal Of Vascular And Interventional Radiology 2015, 26: s5-s6. DOI: 10.1016/j.jvir.2014.12.028.Peer-Reviewed Original ResearchIVC filtrationTrials